Navigation Links
Ulcerative Colitis (UC) Sufferers Find UC Quite Disruptive to Many,Aspects of Daily Life

UC medications LIALDA(TM) and PENTASA(R) (mesalamines). Please see Important Safety Information included below.

UC patients generally report more stress/depression compared to other diseases

The findings illustrate that UC takes a heavy psychological toll, which is further brought to light when comparing UC patient responses to the survey responses of people with three other chronic health conditions -- migraines, rheumatoid arthritis (RA) and asthma, who were also surveyed as part of UC: NORMAL. Eighty-two percent of UC patients said their condition made life more stressful versus 75 percent of migraine patients, 69 percent of RA patients and 46 percent of asthma patients. Furthermore, 62 percent of UC patients reported feeling sometimes or always depressed about having their condition, versus 49 percent of migraine patients, 52 percent of RA patients and 25 percent of asthma patients.

More than four out of five people (84 percent) with UC say they worry about the long-term health effects of having UC, compared to 45 percent of migraine patients, 72 percent of RA patients and 58 percent of asthma patients. Specific worries most commonly mentioned by UC patients were developing colon cancer, having their colon removed, requiring surgery and public fecal incontinence.

Compliance is a challenge

The survey found that 32 percent of UC patients are not currently taking medication to treat their UC. For patients who are taking medications, compliance is an issue. Of those UC patients taking aminosalicylates (5-ASAs), the first-line therapy and most commonly prescribed class of medication for UC, only about half (54 percent) reported that they have taken all of their 5-ASA medications in the past seven days.

Past studies confirm compliance challenges and report that patients who are noncompliant with their prescribed UC medications have a five-fold greater risk of flare-ups than compliant patients. Traditionally, 5-ASA therapies re
'"/>




Page: 1 2 3 4 5 6 7 8 9

Related medicine technology :

1. AM-Pharma Announces Positive Results of Phase IIa Clinical Trial with Alkaline Phosphatase For Ulcerative Colitis
2. Chi-Med Announces Positive Phase II Proof-of-Concept Data for HMPL-004 in Ulcerative Colitis
3. Long-Term Extension of Ulcerative Colitis Study Shows Remicade Responders Maintained Improvement Through Two Years of Follow-Up
4. Analysis of Ulcerative Colitis (UC) Remission Rates from Long-term Safety Study of Lialda (mesalamine) Presented at DDW
5. Callisto Intends to Move Guanilib into Clinical Trials in Ulcerative Colitis
6. New Survey Finds Troubling Data on American Asthma Sufferers
7. New Study Shows A1c Reduced Safely By Patients With Type 2 Diabetes Using Self-Adjusted Dosing Starting With Once-Daily Insulin Treatment Levemir
8. Phase II Results Show Once-Daily Dosing of Human GLP-1 Analog Liraglutide, Brings Patients to A1c Target
9. New Study Shows A1c Reduced Safely By Patients With Type 2 Diabetes Using Self-Adjusted Dosing Starting With Once-Daily Insulin Treatment Levemir
10. International Movement Disorder Specialists Receive New Information About the Use of Once-Daily Azilect in the Treatment of Parkinsons Disease
11. New Study Analyses Confirm Once-Daily Seroquel XR Extended-Release Tablets as Effective Treatment for Schizophrenia
Post Your Comments:
(Date:10/6/2008)...nt study revealed that drinking polyphenol-rich 10...nges in appetite, energy intake or body,weight, C...umption of 100%,polyphenol-rich Concord grape juic...ssociated with changes in appetite and was shown t... presented at the 49th Annual Meeting of,the Ameri...
(Date:10/3/2008)...JAVIK, Iceland, Oct. 3 /- d...e filing of an investigational new drug,(IND) appl...ule modulator,of phosphodiesterase 4 (PDE4), with ...pound is being developed as a new and potentially ...s and cognitive deficits associated,with Alzheimer...
(Date:10/2/2008).... Robert Weiss, Director of Maryland Laser, Skin a...ractice -, BALTIMORE, Oct. 2 /- Robe...among the first physicians in the U.S. to offer hi...), the latest,state-of-the-art procedure in laser... renowned dermatologist, who is in private practic...
(Date:10/2/2008)...EC CITY, Oct. 2 / AEterna Z...biopharmaceutical company focused on,endocrine the...red the,second stage of patient recruitment for it... luteinizing hormone-releasing hormone (LHRH) agon...he second stage of patient,recruitment was taken f...
Breaking Medicine Technology:Concord Grape Juice Has No Significant Impact on Body Weight 2Concord Grape Juice Has No Significant Impact on Body Weight 3deCODE Files IND for DG071, a Novel PDE4 Modulator Being Developed for Alzheimer's and Other Cognitive Disorders 2deCODE Files IND for DG071, a Novel PDE4 Modulator Being Developed for Alzheimer's and Other Cognitive Disorders 3deCODE Files IND for DG071, a Novel PDE4 Modulator Being Developed for Alzheimer's and Other Cognitive Disorders 4deCODE Files IND for DG071, a Novel PDE4 Modulator Being Developed for Alzheimer's and Other Cognitive Disorders 5DOT Therapy: Newest Breakthrough Technology in Laser Skin Resurfacing 2AEterna Zentaris Reaches 2nd Stage of Patient Recruitment for Phase 2 Trial in Ovarian Cancer with the Innovative LHRH Receptor Targeted Conjugate, AEZS-108 2AEterna Zentaris Reaches 2nd Stage of Patient Recruitment for Phase 2 Trial in Ovarian Cancer with the Innovative LHRH Receptor Targeted Conjugate, AEZS-108 3AEterna Zentaris Reaches 2nd Stage of Patient Recruitment for Phase 2 Trial in Ovarian Cancer with the Innovative LHRH Receptor Targeted Conjugate, AEZS-108 4AEterna Zentaris Reaches 2nd Stage of Patient Recruitment for Phase 2 Trial in Ovarian Cancer with the Innovative LHRH Receptor Targeted Conjugate, AEZS-108 5The Changing Face of Medicine 3A National Medical Fellowships Annual Awards Gala Honors Three Fellows 15636 1The Changing Face of Medicine 3A National Medical Fellowships Annual Awards Gala Honors Three Fellows 15636 2The Changing Face of Medicine 3A National Medical Fellowships Annual Awards Gala Honors Three Fellows 15636 3Eastern Ergonomics Conference June 24 in New York City 3B New One Day Format Focus on Core Ergonomics Education 4333 1Eastern Ergonomics Conference June 24 in New York City 3B New One Day Format Focus on Core Ergonomics Education 4333 2Derma Sciences Reports Fourth Quarter Year End Results for 2007 4330 1Derma Sciences Reports Fourth Quarter Year End Results for 2007 4330 2Derma Sciences Reports Fourth Quarter Year End Results for 2007 4330 3Derma Sciences Reports Fourth Quarter Year End Results for 2007 4330 4Derma Sciences Reports Fourth Quarter Year End Results for 2007 4330 5Study Finds Taxus 28R 29 Drug Eluting Stent Beneficial in Treatment of Large Vessels 1657 1Study Finds Taxus 28R 29 Drug Eluting Stent Beneficial in Treatment of Large Vessels 1657 2Study Finds Taxus 28R 29 Drug Eluting Stent Beneficial in Treatment of Large Vessels 1657 3Study Finds Taxus 28R 29 Drug Eluting Stent Beneficial in Treatment of Large Vessels 1657 4
...e Stent Continues to Show Promise as Future-Genera...RNewswire-FirstCall/ -- Abbott,today announced pos...cal trial evaluating the safety and performance of... for the treatment of,coronary artery disease. Nin...trial, presented today at the EuroPCR meeting,dem...
..., May 22, 2007 /PRNewswire-FirstCall/ -- Forest,La...y announced,that preliminary top-line results from...lind, placebo-controlled pivotal Phase III,study d...ffects of,milnacipran as a treatment of fibromyalg...been able to review initial top-line,results and f...
Other Medicine Technology:Abbott Announces Positive Nine-Month Results From the World's First,Clinical Trial of a Fully Bioabsorbable Drug Eluting Coronary Stent 2Abbott Announces Positive Nine-Month Results From the World's First,Clinical Trial of a Fully Bioabsorbable Drug Eluting Coronary Stent 3Forest Laboratories, Inc. and Cypress Bioscience, Inc. Announce,Positive Results of Phase III Study for Milnacipran as a Treatment,for Fibromyalgia Syndrome 2Forest Laboratories, Inc. and Cypress Bioscience, Inc. Announce,Positive Results of Phase III Study for Milnacipran as a Treatment,for Fibromyalgia Syndrome 3Forest Laboratories, Inc. and Cypress Bioscience, Inc. Announce,Positive Results of Phase III Study for Milnacipran as a Treatment,for Fibromyalgia Syndrome 4Forest Laboratories, Inc. and Cypress Bioscience, Inc. Announce,Positive Results of Phase III Study for Milnacipran as a Treatment,for Fibromyalgia Syndrome 5Forest Laboratories, Inc. and Cypress Bioscience, Inc. Announce,Positive Results of Phase III Study for Milnacipran as a Treatment,for Fibromyalgia Syndrome 6
(Date:10/6/2008)...t. 6 /PRNewswire/ -- Developed in collaboration wi...ades, CA is introducing,Revolutionary Breast Surfa...c Surgery office of Dr. Steve Laverson this week i...he first of its kind, and is based on,breakthrough...with,innovative proprietary software. The XS-300(T...
(Date:10/6/2008)...ct. 6 /PRNewswire/ -- The organizers of Informex a...e on Global Sourcing for the,Pharmaceutical Indust...inceton Marriott in New Jersey USA., The conferen... the,Global Sourcing Council, and boasts an unpara...e likes of Johnson & Johnson, Bristol Myers Squibb...
(Date:10/6/2008)... LegalView recently posted detailed inform...he potentially serious side effects caused by the ... the drug,s potential side effects are the develop... for young adult and child patients. , ...- LegalView, the number one resource for everythin...
(Date:10/6/2008)... Hospital Ship Serving in West Africa Rece...Garden Valley, Texas October 6, 2008 -- www.seamob...l provider of communications services to remote lo...s to the FoxNews channel via satellite to Mercy Sh...ica Mercy. The Africa Mercy is the world,s larges...
Breaking Medicine News(10 mins):Health News:Plan Your Breasts in 3-D 2Health News:Global Sourcing Strategies for the Pharmaceutical Industry 10th - 11th November, Marriott Princeton, New Jersey USA 2Health News:LegalView Informs Patients of Possible Cimzia Cancer Link, Drug Commonly Used to Treat Arthritis 2Health News:LegalView Informs Patients of Possible Cimzia Cancer Link, Drug Commonly Used to Treat Arthritis 3Health News:Seamobile Provides Foxnews To Mercy Ships 2Health News:Seamobile Provides Foxnews To Mercy Ships 3
...lth and tackling health inequalities should lie// ...es an expert in this week’s BMJ. Professor Tim Bl... between local government and the NHS would then b... two sides of health prevention and treatment. Th...
...resuscitation (CPR) as well as adults, finds a stu...st that children as young as nine years old should.... Bystander CPR more than doubles the chance of s...arrest. Chest compressions are thought to be the m...
...a far more sensible way of fighting the malady of ...n fact prescription drugs to prevent diabetes cann... effective, they stress. Trials show rosiglitazon...eight loss, which is a safer and cheaper way to av...
... bipolar disorder first appear in childhood or ado...t //to distinguish bipolar symptoms from those of ...arvard Mental Health Letter. Children, especially...he adult cycle of distinct mood episodes of mania ...
Other Medicine News:Health News:Local Councils Should Be Responsible for Tackling Health Inequalities 2Health News:Lifestyle changes not prescription drugs to fight diabetes, say scientists 2
Para 12 Plus is a hematology control for the Abbott CELL-DYN 3000, 3200, and 3500/3700. Assay values are provided for the five-part white cell differential, as well as a three-part differential on th
Indicated to facilitate the intra-luminal placement of conventional guidewires beyond stenotic lesions, including chronic total coronary occlusions.
... 5X is a whole blood hematology control manufactur...0, and the Coulter AcT5diff instruments. The compo...differential, positioning the populations within t...he product offers 105-day closed-vial stability an...
...-Chex is a spinal and body fluid control with dist... the same manner as a patient sample, the white bl...trol is assayed for manual cell counting, the five...e two-part polymorphonuclear and mononuclear diffe...
Medicine Products: